{"downloaded": true, "htmlmade": false, "full": {"id": "29703749", "source": "MED", "pmid": "29703749", "pmcid": "PMC5993622", "fullTextIdList": {"fullTextId": "PMC5993622"}, "doi": "10.1161/circresaha.118.312978", "title": "Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure).", "authorString": "Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JAC, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moy\u00e9 L, Ebert RF, Simari RD, Cardiovascular Cell Therapy Research Network (CCTRN).", "authorList": {"author": [{"fullName": "Bolli R", "firstName": "Roberto", "lastName": "Bolli", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From the Division of Cardiovascular Medicine, University of Louisville, KY (R.B., J.L.)."}}}, {"fullName": "Hare JM", "firstName": "Joshua M", "lastName": "Hare", "initials": "JM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (J.M.H., A.K., R.D.M., I.H.-S.)."}}}, {"fullName": "March KL", "firstName": "Keith L", "lastName": "March", "initials": "KL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Cardiovascular Medicine, UFHealth at University of Florida, Gainesville (K.L.M., C.J.P.)."}}}, {"fullName": "Pepine CJ", "firstName": "Carl J", "lastName": "Pepine", "initials": "CJ", "authorId": {"@type": "ORCID", "#text": "0000-0002-6011-681X"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Cardiovascular Medicine, UFHealth at University of Florida, Gainesville (K.L.M., C.J.P.)."}}}, {"fullName": "Willerson JT", "firstName": "James T", "lastName": "Willerson", "initials": "JT", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Texas Heart Institute, CHI St. Luke's Health, Houston (J.T.W., E.C.P., D.A.T.)."}}}, {"fullName": "Perin EC", "firstName": "Emerson C", "lastName": "Perin", "initials": "EC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Texas Heart Institute, CHI St. Luke's Health, Houston (J.T.W., E.C.P., D.A.T.)."}}}, {"fullName": "Yang PC", "firstName": "Phillip C", "lastName": "Yang", "initials": "PC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Cardiovascular Medicine, Stanford University School of Medicine, CA (P.C.Y.)."}}}, {"fullName": "Henry TD", "firstName": "Timothy D", "lastName": "Henry", "initials": "TD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.)."}}}, {"fullName": "Traverse JH", "firstName": "Jay H", "lastName": "Traverse", "initials": "JH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, MN (J.H.T.)."}}}, {"fullName": "Mitrani RD", "firstName": "Raul D", "lastName": "Mitrani", "initials": "RD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (J.M.H., A.K., R.D.M., I.H.-S.)."}}}, {"fullName": "Khan A", "firstName": "Aisha", "lastName": "Khan", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From the Division of Cardiovascular Medicine, University of Louisville, KY (R.B., J.L.)."}}}, {"fullName": "Hernandez-Schulman I", "firstName": "Ivonne", "lastName": "Hernandez-Schulman", "initials": "I", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (J.M.H., A.K., R.D.M., I.H.-S.)."}}}, {"fullName": "Taylor DA", "firstName": "Doris A", "lastName": "Taylor", "initials": "DA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Texas Heart Institute, CHI St. Luke's Health, Houston (J.T.W., E.C.P., D.A.T.)."}}}, {"fullName": "DiFede DL", "firstName": "Darcy L", "lastName": "DiFede", "initials": "DL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Biological Consulting, LLC, Miami, FL (D.L.D.)."}}}, {"fullName": "Lima JAC", "firstName": "Jo\u00e3o A C", "lastName": "Lima", "initials": "JAC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Cardiology, Johns Hopkins University, Baltimore, MD (J.A.C.L.)."}}}, {"fullName": "Chugh A", "firstName": "Atul", "lastName": "Chugh", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Franciscan Saint Francis Health, Indianapolis, IN (A.C.)."}}}, {"fullName": "Loughran J", "firstName": "John", "lastName": "Loughran", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "From the Division of Cardiovascular Medicine, University of Louisville, KY (R.B., J.L.)."}}}, {"fullName": "Vojvodic RW", "firstName": "Rachel W", "lastName": "Vojvodic", "initials": "RW", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Coordinating Center for Clinical Trials, UT Health School of Public Health, Houston, TX (R.W.V., S.L.S., J.B., M.C., L.M.)."}}}, {"fullName": "Sayre SL", "firstName": "Shelly L", "lastName": "Sayre", "initials": "SL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Coordinating Center for Clinical Trials, UT Health School of Public Health, Houston, TX (R.W.V., S.L.S., J.B., M.C., L.M.)."}}}, {"fullName": "Bettencourt J", "firstName": "Judy", "lastName": "Bettencourt", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Coordinating Center for Clinical Trials, UT Health School of Public Health, Houston, TX (R.W.V., S.L.S., J.B., M.C., L.M.)."}}}, {"fullName": "Cohen M", "firstName": "Michelle", "lastName": "Cohen", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Coordinating Center for Clinical Trials, UT Health School of Public Health, Houston, TX (R.W.V., S.L.S., J.B., M.C., L.M.)."}}}, {"fullName": "Moy\u00e9 L", "firstName": "Lem", "lastName": "Moy\u00e9", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Coordinating Center for Clinical Trials, UT Health School of Public Health, Houston, TX (R.W.V., S.L.S., J.B., M.C., L.M.) lemmoye@msn.com."}}}, {"fullName": "Ebert RF", "firstName": "Ray F", "lastName": "Ebert", "initials": "RF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "NIH, National Heart, Lung, and Blood Institute, Division of Cardiovascular Sciences, Bethesda, MD (R.F.E.)."}}}, {"fullName": "Simari RD", "firstName": "Robert D", "lastName": "Simari", "initials": "RD"}, {"collectiveName": "Cardiovascular Cell Therapy Research Network (CCTRN)"}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-2814-2321"}, {"@type": "ORCID", "#text": "0000-0002-6011-681X"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "12", "volume": "122", "journalIssueId": "2694545", "dateOfPublication": "2018 Jun", "monthOfPublication": "6", "yearOfPublication": "2018", "printPublicationDate": "2018-06-01", "journal": {"title": "Circulation research", "ISOAbbreviation": "Circ Res", "medlineAbbreviation": "Circ Res", "NLMid": "0047103", "ISSN": "0009-7330", "ESSN": "1524-4571"}}, "pubYear": "2018", "pageInfo": "1703-1715", "abstractText": "<h4>Rationale</h4>Autologous bone marrow mesenchymal stem cells (MSCs) and c-kit<sup>+</sup> cardiac progenitor cells (CPCs) are 2 promising cell types being evaluated for patients with heart failure (HF) secondary to ischemic cardiomyopathy. No information is available in humans about the relative efficacy of MSCs and CPCs and whether their combination is more efficacious than either cell type alone.<h4>Objective</h4>CONCERT-HF (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure) is a phase II trial aimed at elucidating these issues by assessing the feasibility, safety, and efficacy of transendocardial administration of autologous MSCs and CPCs, alone and in combination, in patients with HF caused by chronic ischemic cardiomyopathy (coronary artery disease and old myocardial infarction).<h4>Methods and results</h4>Using a randomized, double-blinded, placebo-controlled, multicenter, multitreatment, and adaptive design, CONCERT-HF examines whether administration of MSCs alone, CPCs alone, or MSCs+CPCs in this population alleviates left ventricular remodeling and dysfunction, reduces scar size, improves quality of life, or augments functional capacity. The 4-arm design enables comparisons of MSCs alone with CPCs alone and with their combination. CONCERT-HF consists of 162 patients, 18 in a safety lead-in phase (stage 1) and 144 in the main trial (stage 2). Stage 1 is complete, and stage 2 is currently randomizing patients from 7 centers across the United States.<h4>Conclusions</h4>CONCERT-HF will provide important insights into the potential therapeutic utility of MSCs and CPCs, given alone and in combination, for patients with HF secondary to ischemic cardiomyopathy.<h4>Clinical trial registration</h4>URL: http://www.clinicaltrials.gov. Unique identifier: NCT02501811.", "affiliation": "From the Division of Cardiovascular Medicine, University of Louisville, KY (R.B., J.L.).", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "research-article", "Multicenter Study", "Randomized Controlled Trial", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "UM1 HL087318", "agency": "NHLBI NIH HHS", "acronym": "HL", "orderIn": "0"}, {"grantId": "R01 HL134558", "agency": "NHLBI NIH HHS", "acronym": "HL", "orderIn": "0"}, {"grantId": "UM1 HL087394", "agency": "NHLBI NIH HHS", "acronym": "HL", "orderIn": "0"}, {"grantId": "UM1 HL113460", "agency": "NHLBI NIH HHS", "acronym": "HL", "orderIn": "0"}, {"grantId": "UM1 HL087366", "agency": "NHLBI NIH HHS", "acronym": "HL", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Myocytes, Cardiac", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CY", "qualifierName": "cytology", "majorTopic_YN": "Y"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Myocardial Ischemia", "meshQualifierList": {"meshQualifier": {"abbreviation": "CO", "qualifierName": "complications", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Ventricular Dysfunction, Left", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ET", "qualifierName": "etiology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Combined Modality Therapy", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Stem Cell Transplantation", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Mesenchymal Stem Cell Transplantation", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Transplantation, Autologous"}, {"majorTopic_YN": "N", "descriptorName": "Feasibility Studies"}, {"majorTopic_YN": "N", "descriptorName": "Double-Blind Method"}, {"majorTopic_YN": "N", "descriptorName": "Ventricular Remodeling"}, {"majorTopic_YN": "N", "descriptorName": "Research Design"}, {"majorTopic_YN": "N", "descriptorName": "Proto-Oncogene Proteins c-kit"}, {"majorTopic_YN": "N", "descriptorName": "Heart Failure", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ET", "qualifierName": "etiology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}]}}]}, "keywordList": {"keyword": ["Heart Failure", "coronary artery disease", "Clinical Trial", "Cell-based Therapy"]}, "chemicalList": {"chemical": {"name": "Proto-Oncogene Proteins c-kit", "registryNumber": "EC 2.7.10.1"}}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1161/CIRCRESAHA.118.312978"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5993622"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5993622?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1161/circresaha.118.312978"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "23", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS963509", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-09-19", "dateOfCreation": "2018-04-29", "firstIndexDate": "2018-04-29", "fullTextReceivedDate": "2020-10-21", "dateOfRevision": "2021-01-11", "electronicPublicationDate": "2018-04-27", "firstPublicationDate": "2018-04-27", "embargoDate": "2019-06-08"}, "abstract": "<h4>Rationale</h4>Autologous bone marrow mesenchymal stem cells (MSCs) and c-kit<sup>+</sup> cardiac progenitor cells (CPCs) are 2 promising cell types being evaluated for patients with heart failure (HF) secondary to ischemic cardiomyopathy. No information is available in humans about the relative efficacy of MSCs and CPCs and whether their combination is more efficacious than either cell type alone.<h4>Objective</h4>CONCERT-HF (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure) is a phase II trial aimed at elucidating these issues by assessing the feasibility, safety, and efficacy of transendocardial administration of autologous MSCs and CPCs, alone and in combination, in patients with HF caused by chronic ischemic cardiomyopathy (coronary artery disease and old myocardial infarction).<h4>Methods and results</h4>Using a randomized, double-blinded, placebo-controlled, multicenter, multitreatment, and adaptive design, CONCERT-HF examines whether administration of MSCs alone, CPCs alone, or MSCs+CPCs in this population alleviates left ventricular remodeling and dysfunction, reduces scar size, improves quality of life, or augments functional capacity. The 4-arm design enables comparisons of MSCs alone with CPCs alone and with their combination. CONCERT-HF consists of 162 patients, 18 in a safety lead-in phase (stage 1) and 144 in the main trial (stage 2). Stage 1 is complete, and stage 2 is currently randomizing patients from 7 centers across the United States.<h4>Conclusions</h4>CONCERT-HF will provide important insights into the potential therapeutic utility of MSCs and CPCs, given alone and in combination, for patients with HF secondary to ischemic cardiomyopathy.<h4>Clinical trial registration</h4>URL: http://www.clinicaltrials.gov. Unique identifier: NCT02501811.", "Keywords": ["Heart Failure", "coronary artery disease", "Clinical Trial", "Cell-based Therapy"], "journaltitle": "Circulation research", "title": "Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)."}